Resumen
Urothelial carcinoma is a malignancy of the cells lining the genitourinary tract but it most commonly occurs in the bladder. Once urothelial carcinoma has spread outside of the genitourinary tract, survival outcomes are poor despite the standard of care treatment of chemotherapy followed by immunotherapy. Genetic sequencing of cancer tissue has identified targets for new anti-cancer drugs. This review summarizes the evidence regarding the efficacy of targeted therapies in advanced urothelial carcinoma.